Platelet-Covered Nanocarriers for Targeted Delivery of Hirudin to Eliminate Thrombotic Complication in Tumor Therapy
Source abstract
Abstract
Most patients are at high risk of thrombosis during cancer treatment. However, the major discrepancy in the therapeutic mechanisms and microenvironment between tumors and thrombosis makes it challenging for a panacea to treat cancer while being able to eliminate the risk of thrombosis. Herein, we developed a biomimetic MnOx/Ag2S nanoflower platform with platelet membrane modification (MnOx@Ag2S@hirudin@platelet membrane: MAHP) for the long-term release of anticoagulant drugs to treat thrombosis together with tumor therapy. This MAHP platform could achieve the targeted delivery of hirudin to the thrombus site and perform the controlled release under the irradiation of near-infrared light, demonstrating effective removal of the thrombus. Moreover, MAHP could inhibit tumor progression and prolong the survival time of mice with thromboembolic complications.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Extracellular vesicles in disease · Nanoplatforms for cancer theranostics · Inflammatory Biomarkers in Disease Prognosis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
The State Key Laboratory of Agricultural Microbiology, College of Life Science and Technology, College of Science, Huazhong Agricultural University, Wuhan 430070, Hubei, People’s Republic of China
School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, 21 Nanyang Link, Singapore, 637371, Singapore
Department of Biochemistry, Faculty of Agriculture, Benha University, Moshtohor, Toukh 13736, Egypt
Funding
Ministry of Science and Technology of the People's Republic of China
References (43)
Show source-provided references
1. 10.1093/neuros/nyaa33510.1093/neuros/nyaa335 ↗
2. 10.2147/EB.S27232610.2147/EB.S272326 ↗
3. 10.1182/blood-2006-10-05373610.1182/blood-2006-10-053736 ↗
4. 10.1016/j.critrevonc.2017.08.00310.1016/j.critrevonc.2017.08.003 ↗
5. 10.1186/s12989-019-0292-610.1186/s12989-019-0292-6 ↗
6. 10.1016/S0049-3848(14)50001-110.1016/S0049-3848(14)50001-1 ↗
7. 10.1056/NEJMp03008610.1056/NEJMp030086 ↗
8. 10.1182/blood-2013-04-46012110.1182/blood-2013-04-460121 ↗
9. 10.1002/acg2.7310.1002/acg2.73 ↗
10. 10.1016/j.blre.2015.07.00110.1016/j.blre.2015.07.001 ↗
11. 10.1002/adma.20160346310.1002/adma.201603463 ↗
12. 10.1016/j.msec.2020.11069710.1016/j.msec.2020.110697 ↗
13. 10.1002/smll.20200164710.1002/smll.202001647 ↗
14. 10.1016/j.ccr.2005.05.02410.1016/j.ccr.2005.05.024 ↗
15. 10.1126/sciadv.abc038210.1126/sciadv.abc0382 ↗
16. 10.1126/science.237492610.1126/science.2374926 ↗
17. 10.1021/acsnano.7b0772010.1021/acsnano.7b07720 ↗
18. 10.1039/D0TB00735H10.1039/D0TB00735H ↗
19. 10.1021/acsnano.9b0858710.1021/acsnano.9b08587 ↗
20. 10.1002/anie.20200511110.1002/anie.202005111 ↗
21. 10.1002/adma.20190040110.1002/adma.201900401 ↗
22. 10.1016/j.biomaterials.2015.11.02410.1016/j.biomaterials.2015.11.024 ↗
23. 10.1021/jp064341w10.1021/jp064341w ↗
24. 10.1002/advs.20190137810.1002/advs.201901378 ↗
25. 10.1161/CIRCULATIONAHA.112.00096610.1161/CIRCULATIONAHA.112.000966 ↗
26. 10.1161/01.ATV.0000145574.90840.7d10.1161/01.ATV.0000145574.90840.7d ↗
27. 10.1016/j.nantod.2020.10098610.1016/j.nantod.2020.100986 ↗
28. 10.1039/D0BM02125C10.1039/D0BM02125C ↗
29. 10.1002/adma.20210374810.1002/adma.202103748 ↗
30. 10.1002/anie.20171202710.1002/anie.201712027 ↗
31. 10.1002/adma.20200854010.1002/adma.202008540 ↗
32. 10.1016/j.cej.2019.12284810.1016/j.cej.2019.122848 ↗
33. 10.1002/smll.20200170410.1002/smll.202001704 ↗
34. 10.1002/adma.20170675910.1002/adma.201706759 ↗
35. 10.1039/D0TB00789G10.1039/D0TB00789G ↗
36. 10.2353/ajpath.2010.10020510.2353/ajpath.2010.100205 ↗
37. 10.1182/blood-2010-01-26120610.1182/blood-2010-01-261206 ↗
38. 10.1093/jnci/dji13010.1093/jnci/dji130 ↗
39. 10.1038/s41551-020-0573-210.1038/s41551-020-0573-2 ↗
40. 10.1586/14737140.8.8.124710.1586/14737140.8.8.1247 ↗
41. 10.1038/nrc300410.1038/nrc3004 ↗
42. 10.1158/0008-5472.CAN-15-096410.1158/0008-5472.CAN-15-0964 ↗
43. 10.1002/advs.20210426410.1002/advs.202104264 ↗